Insmed heads into its August earnings window with the most notable story sitting not in options or analyst desks, but in a sharp and sudden retreat of short sellers — even as insiders quietly sell into the rally.
Short interest has dropped by nearly 17% over the past week, falling to 7.2% of the free float — from around 8.7% just days prior. The move is meaningful. From mid-June through early July, shorts had built positions above 9% of float, peaking near 19.7 million shares on June 22. Then, on July 9 and July 10, roughly 3.1 million shares of short interest vanished in two sessions. That is a rapid cover, not a gradual drift. Borrow conditions tell a similar story: availability is extraordinarily loose, now running above 4,300% — meaning the lending pool holds more than 43 shares available for every one currently borrowed. That level of availability has expanded sharply from the 1,700–1,900% range seen in mid-June, when short positioning was at its heaviest. Cost to borrow, though rising 29% on the week to around 0.51%, remains firmly in "low" territory and poses no meaningful constraint. Borrow costs at this level simply do not reflect squeeze pressure. The ORTEX short score has eased from around 50 to 45.5 over the same period — directionally consistent with a market that is pulling back bearish positioning rather than adding to it.
Options tell a mildly more cautious story. The put/call ratio moved to 0.63 on July 14, slightly above its 20-day average near 0.60 — about 1.4 standard deviations elevated, though well short of the 52-week high of 1.18. The read here is that options traders are not yet alarmed, but they are showing more interest in downside protection than the recent norm. With the next earnings print confirmed for August 6, that gentle lean toward puts is not unreasonable.
Analyst conviction remains broadly positive, though targets have been drifting lower since the May earnings disappointment. Wells Fargo lifted its target marginally to $161 this week while maintaining Overweight, and Guggenheim reiterated Buy with a $207 target last week. JPMorgan trimmed its target to $179 in early June, still carrying Overweight. The direction of travel across the Street since May 8 has been target reductions while holding positive ratings — a pattern that reflects confidence in the Brinsupri and Arikayce commercial story, offset by more tempered modelling assumptions after the Q1 print. The consensus mean target of $197 implies roughly 79% upside to the current $110 price, though the Street's targets in aggregate look significantly above where the stock trades — a gap that has been persistent in this name and is partly a function of binary pipeline optionality being baked into bull-case numbers. The forward 12-month earnings growth factor ranks in the 97th percentile, reflecting the rapid revenue ramp, while EPS momentum over 30 and 90 days sits in the bottom decile — the growth is there but estimate revisions have been negative in the near term.
On insider activity, the pattern is harder to ignore. CEO Will Lewis sold shares on three separate dates — June 25, July 6, and July 9 — totalling over $2.2 million across the cluster. The CMO also sold just over $1.35 million worth on July 6. These are relatively small as a percentage of the company, and all scored low on the ORTEX significance scale, suggesting they are likely part of pre-arranged trading plans. The aggregate 90-day insider net figure shows a small positive balance in share count terms, reflecting options exercises elsewhere, but the recent cash-out pattern from the two most senior officers around the $103–$119 level is worth tracking as the stock approaches August's catalyst.
Institutional ownership remains well distributed, with JP Morgan Asset Management and BlackRock each adding meaningfully in the quarter to June 30. Fidelity grew its position by over 3.2 million shares to reach 6% of shares outstanding — a material addition that reinforces the commercial growth case. Peers had a rough week: ALNY dropped 12.5% and SRPT fell 9.2%, while INSM gave back only 2.4% — a degree of relative resilience that may partly explain why shorts chose this week to cover.
The August 6 earnings date is the next focal point: with short interest having just compressed sharply and options showing only mild defensiveness, the setup into that print will be worth monitoring as positions either rebuild or continue to unwind.
See the live data behind this article on ORTEX.
Open INSM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
